Results 81 to 90 of about 6,976 (185)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer

, 2022
Igor Makhlin, Angela DeMichele
openalex   +1 more source

Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology

Regulatory Mechanisms in Biosystems
In 2022, 2.3 million new cases of breast cancer were registered in the world, which accounted for 11.6% of the total number of malignant neoplasms. Depending on the tumor's molecular profile, the prognosis for patients can be different.
O. Vynnychenko, R. Moskalenko
doaj   +1 more source

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
BackgroundAntibody-drug conjugates (ADCs) have emerged as the focus and hotspots in the cancer field, yet the accompanying ocular toxicity has often been underestimated.
KaiLi Mao, Ping Chen, HuaYu Sun, SongYang Zhong, HongLiang Zheng, LuYao Xu   +5 more
doaj   +1 more source

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer

Breast Cancer Research
Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment risk factors for pneumonitis associated with T-DXd ...
Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho   +15 more
doaj   +1 more source

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice [PDF]

Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Giovanni Mariani, D. Aldrighetti, Giampaolo Bianchini, Luca Licata   +12 more
openalex   +1 more source

Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report

, 2022
Takatsugu Ogata, Yasuko Fujita, Kei Muro
openalex   +1 more source

Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series

Frontiers in Oncology
BackgroundHuman epidermal growth factor receptor 2 protein (HER2)-positive (+) metastatic breast cancer (MBC) is an aggressive disease and patients often undergo multiple lines of therapy following HER2 targeted therapies.
Reshma Mahtani, Reshma Mahtani, Reshma Mahtani, Natasha Harpalani, Fengting Yan, Fengting Yan, Kristen Phiel, Iuliia Kovalenko   +7 more
doaj   +1 more source

186P Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients With HER2+ or HER2-low unresectable and/or metastatic breast cancer (mBC) in DESTINY-Breast trials [PDF]

Y.H. Park, W. Jacot, S.A. Hurvitz, S. Modi, Toshinari Yamashita, Baojun Xu, E. Tokunaga, X. Wang, K.S. Lee, Hitoshi Iwata, I. Krop, Fabrice André, N. Harbeck, H.S. Rugo, E. Mathias, Waltraud Pasteiner, Maha Karnoub, Shahid Ashfaque, Yun Cheng, S-B. Kim   +19 more
openalex   +1 more source

Life-Saving Reduced Dose of Trastuzumab-Deruxtecan in Metastatic HER2-Low Metastatic Breast Cancer with Major Hepatic Insufficiency: A Case Report [PDF]

Nahed Damaj, Ghida Diab, Gilbert Freiha, Bryan Youssef, Joseph Amara, Celina Douaihy, Lina Menassa, Lynn Abdo, Serge Fenianos, Elie Haddad, Georges Dabar, Roland Eid, Hampig Raphaël Kourie   +12 more
openalex   +1 more source

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) [PDF]

Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Takashi Yamanaka, K. Aogi, Koji Matsumoto, T. Iwasa, Michio Tokiwa, Michiko Tsuneizumi, Y. Miyoshi, Chiyoe Kitagawa, Mari Yamamoto, Yaoko Takano, Chiyo K. Imamura, Yasutaka Chiba, Daisuke Takiguchi, Tutomu Ezumi, Toshimi Takano   +19 more
openalex   +1 more source